Home » Aeterna Zentaris announces $1.

Aeterna Zentaris announces $1.

Jacek Pinski, Associate Professor of Medicine at the Norris In depth Cancer Center of the University of Southern California, a grant around US$1.5 million over 3 years to conduct a Phase 1/2 study in refractory prostate cancer with the Company’s doxorubicin LHRH receptor targeted conjugate compound, AEZS-108. The study, entitled A Phase I/II Trial of AN-152 in Castration – and Taxane-Resistant Prostate Malignancy , will enroll up to 55 patients and will be conducted in two portions: the first portion will end up being an abbreviated dose-escalation followed by an individual arm, Simon Optimum two-stage design Phase 2 study using the dosage selected in the Stage 1 portion. The primary objective of the Phase 2 part is to evaluate the clinical good thing about AEZS-108 in men with castration – and taxane-resistant metastatic prostate cancer, for which the current presence of LHRH receptors provides been verified.The complication rate for reconstruction in females who acquired bilateral prophylactic mastectomy was 3 % and ten % for those who got unilateral prophylactic mastectomy. Additionally, the analysis noted the cosmetic evaluation for all sufferers was a score of 3 out of 4. These women appear and feel the same or better and their risk of cancer has been removed the table, stated Dr. Spear. For females who understand they are in risk, this program gives them the chance to be active about their appearance and health instead of reactive.